Bal Pharma Ltd

Know More
NSEBSE

105.25-0.95 (-0.89%)

12:00 AM,8th Dec 2023

105.10-1.40 (-1.31%)

12:00 AM,8th Dec 2023

BSE : 524824

NSE : BALPHARMA

Sector : Health care

ISIN Code : INE083D01012

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Dec 08 2023 | 12:00 AM IST

Market Cap (₹ Cr)

166

Turnover (₹ Cr)

0.03

Volume (Shares)

33084

Face Value

10

52-WK High

118.35

52-WK High Date

16 Nov 2023

52-WK Low

63.35

52-WK Low Date

29 Mar 2023

All Time High

167.90

All Time High Date

13 Jan 2016

All Time Low

13.00

All Time Low Date

21 Jun 2013

Bal Pharma Ltd

Bal Pharma (BPL) a member of the Mcro Laboratories group was incorporated as a private limited company in May '87. In Mar.'90 BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations -- paracetamol aluminium hydroxide povidone iodine alprazolam gliclazide griseofulvin lactobacillus rifampicin piroxicam amoxycillin etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 1997-98 the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN CAFIMOL & CORTIDERM.The company has added further product range Zanovid Aziwin Dry Syrup Meloxi Ocium - M Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range the company has introduced Cardiac Specialities Products. To market these products a new division named SERVETUS has started functioning during 2001. New products like AmilorideBenzydamine and Ebastine were rolled into the market during 2002.

Bal Pharma Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

166

EPS - TTM (₹) [S]

4.04

P/E Ratio (X) [S]

1.71

Face Value (₹) 10
Latest Dividend (%)10.00
Latest Dividend Date 18 Sep 2023
Dividend Yield (%) 0.94
Book Value Share (₹) [S]61.62
P/B Ratio (₹) [S]1.71
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

103.00

110.00

Week Low/High

103.00

110.00

Month Low/High

91.20

118.00

Year Low/High

63.35

118.00

All time Low/High

1.60

168.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-0.19%0.19%3.473.46%
1 Month13.75%13.60%7.467.85%
3 Month6.82%6.85%4.845.80%
6 Month18.70%18.46%11.1012.53%
1 Year17.47%17.60%11.5912.68%
3 Year75.71%80.07%53.1056.57%

Company Info

Company Information

Managing Director : Shailesh Siroya

Independent Director : C V Srinivas

Executive Director : Himesh Virupakshaya

Independent Director : H S Venkatesh

Independent Director : Nicola Neeladri

Independent Director : Jatish Sheth

Whole-time Director : Kotian Chittananda Damodar

Company Sec. & Compli. Officer : Abdul Basith

Registered Office: 21 & 22 Bommasandra Indl Area, Hosur Road,Bangalore,Karnataka-560092 Ph:

Email:secretarial@balpharma.com/info@balpharma.com

URL:http://www.balpharma.com